Pharmaceuticals
Subgroup Analysis from Pivotal WU-KONG1B Study Exhibits Robust Efficacy of Sunvozertinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations Across Different Baseline Characteristics
Results of subgroup analysis from the pivotal WU-KONG1B study in relapsed or refractory NSCLC with EGFR exon20ins presented at ESMO 2024 * Sunvozertinib demonstrated promising anti-tumor efficacy, regardless of EGFR exon20ins region classification, race, region, baseline brain metastasis, prio...
2024-09-17 15:47
2600
WestGene Biopharma Presents Groundbreaking mRNA Vaccine Data at ESMO 2024
BARCELONA, Spain, Sept. 16, 2024 /PRNewswire/ -- WestGene Biopharma, a leading innovator in mRNA therapeutics, presented the latest clinical data for its EBV-positive tumour mRNA vaccine, WGc-043, during a mini-oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024. ...
2024-09-17 00:01
1933
Vazyme Leads Life Science Innovation, Boosting Research Breakthroughs in mIDH1 Cancer Treatment
NANJING, China, Sept. 16, 2024 /PRNewswire/ -- Vazyme (688105.SH), a leading life science technology company, significantly contributed to groundbreaking research published in Science Magazine through its innovative products. The study, which focuses on how mutant IDH1 inhibition activates tumor ...
2024-09-16 19:00
2492
Antennova Releases Latest Data of CD73 Inhibitor ATN-037, including a DCR of 89.5%, in a Mini Oral at ESMO Congress 2024
* In patients with non-small cell lung cancer (NSCLC) or melanoma who had acquired resistance to checkpoint inhibitors (CPIs), ATN-037 in combination with KEYTRUDA®(pembrolizumab) demonstrated an overall response rate (ORR) of 21.1% and a disease control rate (DCR) of 89.5%. * Data from the...
2024-09-16 18:00
2830
Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration
NANJING, China, Sept. 14, 2024 /PRNewswire/ -- On September 2, 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tablets), an innovative drug for stroke, has been granted the Breakthrough Therapy designation by the U...
2024-09-14 19:43
4518
Harbour BioMed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Sept. 14, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immuno...
2024-09-14 16:06
4448
MediLink presents YL201 (B7H3 ADC) at ESMO 2024, with over 6-months PFS in SCLC, and showing pan-tumor benefits
* The first publication of clinical data for YL201, featured in an oral presentation at ESMO 2024. * Encouraging antitumor activity of YL201 in multiple solid tumor types, including SCLC, NPC, and wild-type NSCLC, from Phase I escalation and expansion results. * In extensive-stage SCLC pati...
2024-09-14 01:00
3555
US FDA Grants RPD Designation to Senhwa Biosciences Silmitasertib for Pediatric Neuroblastoma
TAIPEI and SAN DIEGO, Sept. 13, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that its new drug Silmitasertib (CX-4945) was granted a rare pe...
2024-09-13 13:49
1797
Nona Biosciences Enters into Collaboration Agreement with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies
CAMBRIDGE, Mass., Sept. 12, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), announced today that it has entered into a multi-target antibody discovery collaboration with Umoja Biopharma, a transformative immunotherapy...
2024-09-13 09:27
2126
Stapokibart Was Granted Marketing Approval From National Medical Products Administration For The Treatment Of Moderate-to-severe Atopic Dermatitis in Adults
CHENGDU, China, Sept.12, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") ofChina has recently approved the new drug application for Stapokibart (anti-IL-4Rα monoclonal antibody, trade name:Kangyueda (康悦达), for th...
2024-09-13 00:07
2585
SECuRE trial advances: No dose limiting toxicities and strong preliminary efficacy data in first multi-dose cohort
Highlights * Cohort 4 of the SECuRE trial is the first to assess multiple cycles of 67 Cu-SAR-bisPSMA at the highest dose of 12GBq. * The Safety Review Committee (SRC) assessed early data from the first 3 participants in cohort 4 who received 2 doses of67Cu-SAR-bisPSMA. Two of these participa...
2024-09-12 21:03
2505
E-Home Household Services Holdings Limited's subsidiary Zhongrun Pharmaceutical and New Zealand's NBL Pharmaceuticals Sign Cooperation Agreement to Expand International Markets
FUZHOU, China, Sept. 12, 2024 /PRNewswire/ -- E-Home Household Services Holdings Limited (NASDAQ:EJH) (the "Company" or "eHome"), an integrated home services provider inChina, announced today that after the detailed business and market due diligence conducted by the Company and the detailed busin...
2024-09-12 21:00
5309
Bloomage 2024 Mid-Year Report: International Raw Materials Sales Surpass Domestic Chinese Market's for the First Time
PARSIPPANY, N.J., Sept. 11, 2024 /PRNewswire/ -- Bloomage, a global leader in hyaluronic acid and other bioactive substance innovations, showcased robust growth in its raw materials business in its newly released 2024 mid-year financial report. The company reported a total revenue ofRMB 2.811 bil...
2024-09-11 21:00
1469
Collagen tripeptides: a new era of collagen drinks
Collagen is highly valued not only for its anti-aging properties but also for its potential benefits in promoting joint health, weight management, and improving overall wellbeing. TAIPEI, Sept. 11, 2024 /PRNewswire/ -- The 2023 global collagen market was valued atUSD 9.76 billion and is projecte...
2024-09-11 17:00
2134
TCI Revolutionizes Weight Management with Breakthrough GLP-1 Innovation
TAIPEI, Sept. 11, 2024 /PRNewswire/ -- TCI Co. Ltd. ("TCI", 8436.TWO), a global leader in ODM health and cosmetic products for over 40 years, introduces its cutting-edge GLP-1 formula, a natural blend of plant extracts, probiotics, and prebiotics designed to deliver powerful weight management res...
2024-09-11 15:56
2474
GC Cell and PT Bifarma Adiluhung sign a licensing agreement for Immuncell-LC to expand access in Indonesia
YONGIN, South Korea, Sept. 10, 2024 /PRNewswire/ -- GC Cell, a leading innovator in cell therapy, has officially announced the execution of a landmark 'Technology Transfer and License Agreement' with PT Bifarma Adiluhung(Bifarma), a premier stem cell therapy company inIndonesia. This strategic pa...
2024-09-11 09:48
2327
Ractigen Announces Positive Clinical Data for RAG-17 in ALS-SOD1 Treatment from Investigator-Initiated Trial
NANTONG, China and SUZHOU, China, Sept. 10, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing innovative therapies, today announced promising clinical data from an Investigator-Initiated Trial (IIT) of RAG-17, a small interfering RNA (siRN...
2024-09-10 20:00
2047
I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer
- Pharmacokinetic/pharmacodynamic (PK/PD) modeling data from three Phase 1 studies providing dosing support for upcoming clinical trials - Exposure-Response (E-R) Analysis showed a positive correlation between uliledlimab concentration and ORR probability in mNSCLC patients - Randomized Phase 2 st...
2024-09-10 19:00
1600
The 2024 International (Bozhou) TCM Expo Kicked Off
BOZHOU, China, Sept. 10, 2024 /PRNewswire/ -- On the morning of September 9, the 2024 International (Bozhou) TCM Expo and the 40th National (Bozhou) TCM Trade Fair officially kicked off in Bozhou,Anhui Province. In recent years, Bozhou has been enhancing mechanisms for the inheritance, innovatio...
2024-09-10 17:55
1319
Bambusa Therapeutics Inc. Announces Successful Series Seed Funding to Advance Innovative Bispecific Antibodies for Immunology & Inflammation
BOSTON, Sept. 9, 2024 /PRNewswire/ -- Bambusa Therapeutics Inc., a biotechnology company focused on developing bispecific antibodies for the treatment of immunological and inflammatory (I&I) disorders, announced the successful closing of its Series Seed financing round, raising approximately$15 ...
2024-09-09 21:09
1889
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 319 media titles]
2026-01-23 11:03
Agoda Launches Agoda Impact Lab at ASEAN Tourism Forum
[Picked up by 318 media titles]
2026-01-29 15:06
Agoda Launches Open-Source API Agent to Simplify MCP Server Integrations
[Picked up by 309 media titles]
2026-01-27 13:00
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 307 media titles]
2026-01-23 09:00Nokia Strengthens Edge AI Capabilities Through Strategic Collaboration with Blaize on Hybrid Inference Solutions Across Asia Pacific Regions
[Picked up by 294 media titles]
2026-01-27 18:00
Most Read
Robo.ai Partners with The Ghazi Group to Power AI Compute Infrastructure Growth in MENA and Southeast Asia
2026-01-23 19:02
8500
